

Special Issue

Hepatitis E Virus (HEV)

Message from the Guest Editors

Hepatitis E virus (HEV) is one of the most important causes of viral hepatitis globally. HEV is actually an umbrella term for a large group of variants, many of which can cause human infections. Through multiple transmission routes (food-borne zoonotic, human-to-human, blood-borne), HEV has established niches in various epidemiological settings. The clinical spectrum of hepatitis E ranges from asymptomatic infection to fulminant hepatitis. Extrahepatic manifestations are increasingly recognized and immunocompromised patients are prone to persistent infections. This Special Issue 'Hepatitis E Virus (HEV)' seeks to publish high-quality original research and review articles on unanswered questions in the field of hepatitis E pathogenesis, epidemiology, clinical management, and control. Both clinical research and basic research with translational relevance are welcome.

Guest Editors

Dr. Siddharth Sridhar

State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China

Prof. Dr. Philip Meuleman

Laboratory of Liver Infectious Diseases, Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium

Deadline for manuscript submissions

closed (25 November 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/106888

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://viruses.mdpi.com)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).